Sign In
Buy TRVI
$13.45
-0.0500 (-0.370%)
At Close: Jun 03, 2026
Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024
07:30am, Thursday, 01'st Aug 2024
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
07:30am, Tuesday, 02'nd Jul 2024
Two abstracts accepted for oral presentation at the 13th London International Cough Symposium NEW HAVEN, Conn. , July 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage
Trevi Therapeutics, Inc. (TRVI) Q1 2024 Earnings Call Transcript
01:56pm, Saturday, 11'th May 2024
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer Lisa Delfini - Chief Financia
Trevi Therapeutics to Participate in Upcoming Conferences
07:30am, Thursday, 09'th May 2024
NEW HAVEN, Conn. , May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
04:05pm, Tuesday, 07'th May 2024
Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of 2024 Topline results continu
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
04:05pm, Wednesday, 01'st May 2024
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:56am, Thursday, 18'th Apr 2024
Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement a
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
07:30am, Tuesday, 09'th Apr 2024
Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in patients with IPF in the CANAL trial NEW HAVEN, Conn. , April 9, 2024 /PRNewswire/ -- Trevi Therapeuti
Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick
09:31am, Thursday, 04'th Apr 2024
Trevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Trevi Therapeutics to Participate in Upcoming April Events
07:30am, Thursday, 04'th Apr 2024
NEW HAVEN, Conn. , April 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
07:30am, Tuesday, 02'nd Apr 2024
Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn. , April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a cl
Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript
06:21pm, Wednesday, 20'th Mar 2024
Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
04:05pm, Wednesday, 20'th Mar 2024
Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data expected in the second half of 2024 Enrollment progressing in the Phase 2b CORAL dose-ranging trial of H
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
04:05pm, Wednesday, 13'th Mar 2024
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Upcoming March Events
07:30am, Wednesday, 28'th Feb 2024
NEW HAVEN, Conn. , Feb. 28, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine
